^
    Back
    Association details:
    Biomarker:RICTOR amplification
    Cancer:Gastric Cancer
    Drug:vistusertib (AZD2014) (mTOR inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy

    Excerpt:
    ...Patients with RICTOR amplification through NGS....
    Trial ID:
    RICTOR_SC
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

    Excerpt:
    ...Patients with RICTOR amplification or overexpression through the VIKTORY trial....
    Trial ID:
    NCT03061708
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Ann Oncol
    Title:

    Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

    Excerpt:
    MTT proliferation assays showed increased sensitivity to the dual mTORC1/2 inhibitor AZD2014 and the dual PI3K/mTOR compound BEZ235 (Figure 2B)...among the various inhibitors tested, AZD2014 showed the most potent inhibitory effect onRICTOR-amplified GC PDCs.
    DOI:
    10.1093/annonc/mdw669